(2026). Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease. FEBS Open Bio.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Treatment with KCL‐286, a First‐in‐class Retinoic Acid Receptor‐β (RARβ) Agonist, Ameliorates Neuronal DNA Damage and Inflammation in a Mouse Model of Alzheimer's Disease."
FEBS Open Bio 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Treatment with KCL‐286, a First‐in‐class Retinoic Acid Receptor‐β (RARβ) Agonist, Ameliorates Neuronal DNA Damage and Inflammation in a Mouse Model of Alzheimer's Disease."
FEBS Open Bio, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.